Aggressive retinopathy of prematurity: characteristics and risk factors for retreatment
- 28 August 2026
- journal article
- Published by BMJ in British Journal of Ophthalmology
Abstract
Background/Aims: Aggressive retinopathy of prematurity (A-ROP) is a severe subtype of ROP that can require repeated treatment yet risk factors for retreatment remain incompletely defined. This study aims to identify risk factors for anti-vascular endothelial growth factor (VEGF) re-injection in A-ROP across US-born and non-US-born infants. Methods: Data from premature infants with ROP were collected across 23 sites (16 USA, 7 non-USA) from 2007 to 2021. A-ROP re-injection risk was evaluated using generalised estimating equations, adjusted for birth weight (BW), gestational age (GA) at birth, ROP zone at injection, hospital site and initial anti-VEGF agent. Results: Of 1677 examined eyes, 1600 had ROP; 283 had A-ROP (mean BW 712 g, mean GA 24.8 weeks) and 1317 had non-A-ROP (mean BW 812 g, mean GA 25.9 weeks). Infants with A-ROP had lower mean BW and GA (p < 0.001). Across A-ROP cases, each 100 g increase in BW decreased re-injection risk by 26% (p=0.041). Compared with bevacizumab, ranibizumab was associated with a higher risk of re-injection in A-ROP eyes (risk ratio=4.82, p=0.009). ROP zone II was associated with a 2.48-fold higher risk of re-injection than zone I (p = 0.014), which was attenuated after correction for bilaterality. Conclusions and relevance: A-ROP is associated with lower BW, lower GA at birth and more posterior ROP zone than non-A-ROP. Lower BW and initial ranibizumab treatment are related to greater risk of repeat anti-VEGF injection. There was more retreatment in zone II A-ROP eyes compared with those in zone I, which did not persist after correction for bilaterality.Keywords
This publication has 42 references indexed in Scilit:
- Retinopathy of Prematurity in the Extremely Premature: Disease Burden, Treatment Approaches, and Visual Outcomes in Micro- and Nano-Premature InfantsAmerican Journal of Ophthalmology, 2025
- Predictive factors of early reactivation after ıntravitreal ranibizumab in agressive retinopathy of prematurityJournal Français d'Ophtalmologie, 2024
- Epidemiology of Retinopathy of Prematurity in the US From 2003 to 2019JAMA Ophthalmology, 2023
- Comparison of bevacizumab, ranibizumab and aflibercept in retinopathy of prematurity treatmentInternational Ophthalmology, 2022
- Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab MonotherapyOphthalmology, 2016
- Risk factors and rate of progression for zone I versus zone II type 1 retinopathy of prematurityJournal of American Association for Pediatric Ophthalmology and Strabismus, 2014
- Intraocular Pharmacokinetics of Ranibizumab Following a Single Intravitreal Injection in HumansAmerican Journal of Ophthalmology, 2012
- Reactivation of Retinopathy of Prematurity After Bevacizumab InjectionArchives of Ophthalmology (1950), 2012
- Pharmacokinetics of Intravitreal Ranibizumab (Lucentis)Ophthalmology, 2007
- Retinopathy of Prematurity: Two Distinct Mechanisms That Underlie Zone 1 and Zone 2 DiseaseAmerican Journal of Ophthalmology, 2006